Investors

Born: 1971
Education and experience: MD, PhD. John Öhd has extensive experience in drug development and has previously worked in several different indication areas, including CNS, cancer and blood diseases. Öhd's previous qualifications include the leadership positions within the research organizations of AstraZeneca and Shire and as Chief Medical Officer at the biotechnology company Medivir.
Other current roles: Chief Scientific Officer at KDventures AB. Board Member at Umecrine Cognition AB, SVF Vaccines AB and Boost Pharma.
Holdings: 3 260 591 shares 

Born: 1967
Education and experience: Master of Sciences in Chemical and administrative sciences from university of Karlstad. Claes Lindblad has over 25 years of broad experience from leading positions in life science. Lindblad has previously been CFO of the Medtech company OssDsign, where he led the company's financial and administrative functions and played a key role in the company's listing on Nasdaq First North Growth Market 2019. Before that, Lindblad has held several senior positions, including as Country manager for the global and market leading Medtec company ConvaTec, and in the role of Sales director for the OTC and generic portfolio at Nycomed / Takeda.
Other current roles: None
Holdings: 79 056 shares.

Born: 1965
Education and experience: MD, PhD, Assoc Prof in Cardiology at Karolinska Institute. Viktor Drvota has over 18 years’ experience from venture capital in life sciences. Drvota was responsible for life science at SEB Venture Capital 2002–2016 and has many years of experience of board duties in biotech and medtech companies.
Other current roles: CEO of KDventures AB and Umecrine Cognition AB . Chairman of the board at Modus Therapeutics AB, Modus Therapeutics Holding AB, Umecrine Cognition AB. Board member at KDev Investments AB, UC Research AB, Dilafor AB, AnaCardio and Dilafor Incentive AB. Deputy board member at Svenska Vaccinfabriken Produktion AB.
Holdings: 0 Shares.
Viktor Drvota is independent in relation to the Company and company management but dependent in relation to the Company's major shareholders.

Born: 1973
Education and experience: Johan Dighed has a Master of Laws from Lund University. Johan Dighed has over 20 years’ experience in financial and business law including positions as Head of Legal with the German bank SEB AG and legal counsel with SEB AB. Prior to joining the financial sector he worked with the international law firm Baker & McKenzie and in the Swedish Judiciary.
Other current roles: Deputy CEO and general counsel at KDventures AB. Board assignments in KDev Investments AB, KDev Invest Consulting AB, KCIF Fund Management, AnaCardio AB, AnaCardio R&D AB, AnaCardio Holding AB, KD Incentive AB, Modus Therapetuics AB, Pharmnovo and Promimic AB (publ).
Holdings: 0 shares.
Johan Dighed is independent in relation to the Company and company management but dependent in relation to the Company's major shareholders.

Born: 1974
Education and experience: PhD in Neuroscience from the Yale School of Medicine. Donnelly has extensive experience from leadership positions within Life Science, including as former CEO of Modus, Abliva and senior positions within Pfizer and Combinato Rx. Ellen Donnelly was previously CEO of Epigenetics Division and Juvenescence and management consultant for MEDACorp / Leerink and Swann Strategic Advisors.
Other current roles: CEO of Neumirna Therapeutics, Board member of Alzecure Pharma AB.
Holdings: 195 073 shares.
Ellen Donnelly is independent in relation to the Company, the Company management and the Company's major shareholders.